Severe (controlled attenuation parameter (CAP) ≥330 dB/m) or mild steatosis (CAP: 298-317 dB / m), and FibroScan® grade 2 fibrosis (M probe: 7-9 kpa; XL probe: 5-7.5 kpa) in patients with grade 1 or 2 obesity and insulin resistance (HOMA index\> 2.6) or diabetes mellitus.
Decompensated NAFLD cirrhosis (i.e. development of ascites, variceal hemorrhage, and/or hepatic encephalopathy) up to Child B (9 points).
Signature of informed consent.
You may not be if
Concomitant liver disease and patients with acute on chronic liver failure.
Excessive alcohol consumption (≥ 30 grams per day in men and ≥ 20 grams per day in women).
Comorbidities (HIV infection, connective diseases, prothrombotic disorders) and/or drugs (didanosine, azathioprine, oxaliplatin) associated with the presence of idiopathic non-cirrhotic portal hypertension.
Clinical history of cardiovascular disease (ischemic cardiomyopathy, atrial fibrillation, valvular defects, severe arterial hypertension, previous hospitalizations secondary to heart failure, cerebrovascular disease).
Severe renal impairment, defined by creatinine clearance \<15 ml/min/1.73m2.
Any previous or current thrombosis in any venous territory.
Uncontrolled psychiatric illness
Contraindication to liver biopsy or any of the complementary tests included in the project.
Hepatocellular carcinoma that does not meet Milan criteria.
Pregnancy or breastfeeding
Significant comorbidities that entail a functional limitation and/or a life expectancy of less than 12 months.
Clareo Health | Portal Hypertension in Non-alcoholic Fatty Liver Disease: Association With Cardiovascular Risk and Identification of Non-invasive Biomarkers (THESIS)
